|
|
Other links at Articles > Hematology-Oncology |
| 3. |
Targeted Therapy for Melanoma: Progress Forward
|
|
|
Researchers describe the results of a phase 1 study of PLX4032, an inhibitor of mutated BRAF, in patients with melanoma. Dr. Maurie Markman looks at the clinical significance of their findings. Medscape Genomic Medicine
|
|
|